Research-based PAM50 signature and long-term breast cancer survival

Abstract

Purpose Multi-gene signatures provide biological insight and risk stratification in breast cancer. Intrinsic molecular subtypes defined by mRNA expression of 50 genes (PAM50) are prognostic in hormone-receptor positive postmenopausal breast cancer. Yet, for 25-40% in the PAM50 intermediate risk group, long-term risk remains uncertain. Our study aimed to (i) test the long-term prognostic value of the PAM50 signature in pre-and post-menopausal breast cancer; (ii) investigate if the PAM50 model could be improved by addition of other mRNAs implicated in oncogenesis. Methods We used archived FFPE samples from 1723 breast cancer survivors; high quality reads were obtained on 1253 samples. Transcript expression was quantified using a custom codeset with probes for > 100 targets. Cox models assessed gene signatures for breast cancer relapse and survival. Results Over 15 + years of follow-up, PAM50 subtypes were (P < 0.01) associated with breast cancer outcomes after accounting for tumor stage, grade and age at diagnosis. Results did not differ by menopausal status at diagnosis. Women with Luminal B (versus Luminal A) subtype had a > 60% higher hazard. Addition of a 13-gene hypoxia signature improved prognostication with > 40% higher hazard in the highest vs lowest hypoxia tertiles. Conclusions PAM50 intrinsic subtypes were independently prognostic for long-term breast cancer survival, irrespective of menopausal status. Addition of hypoxia signatures improved risk prediction. If replicated, incorporating the 13-gene hypoxia signature into the existing PAM50 risk assessment tool, may refine risk stratification and further clarify treatment for breast cancer.

Male breast cancer: clinicopathological characterization of a National Danish cohort 1980–2009

“…We found a significantly better SMR for Luminal A subtype than for Luminal B subtype, also well known from female breast cancer [29,30]. This could indicate the importance of doing molecular subtyping for MBC to distinguish between those patients who will benefit from chemotherapy and those, who will not, if it can be calculated as for postmenopausal FBC.…”

A Novel Ferroptosis-Related Gene Signature Predicts Overall Survival of Breast Cancer Patients

“…The five-year survival rate for breast cancer patients with stages III and IV were 57% and 23.4%, respectively [4]. It is commonly Biology 2021, 10, 151 2 of 15 known that multigene signatures could provide risk stratification and prognostic prediction in breast cancer, such as PAM50 signature [5]. Also, this kind of multigene signature brings insight to molecular biologic characteristics of breast cancer, as transcriptome or related molecular biologic data was the original source of constructing such a prognostic prediction model.…”

Identified the novel resistant biomarkers for taxane-based therapy for triple-negative breast cancer

“…The recent developed gene expression classifier, PAM50, defined by mRNA analysis of 50 genes, is important for therapeutic reference. PAM50 include five subtypes, Luminal A, Luminal B, Basal, Her2-enriched and normal-like 3 . Triple-negative breast cancer (TNBC) means the absence of ER and PR expressions and a lack of amplification of the HER-2 gene 4 , 5 .…”